STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: EC804, a synthetic derivative of indirubin, an active component in a traditional Chinese medicine formulation, was reported to inhibit STAT3 and/or STAT5 phosphorylation as well as the growth of sensitive or TKI-resistant CML and AML cells [286,287].